Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes
- 7 December 2004
- journal article
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 44 (11), 2231-2238
- https://doi.org/10.1016/j.jacc.2004.08.066
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- BH4-domain peptide from Bcl-xL exerts anti-apoptotic activity in vivoOncogene, 2003
- Trastuzumab‐associated cardiotoxicityCancer, 2002
- Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeuticsCancer Cell, 2002
- Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathyProceedings of the National Academy of Sciences, 2002
- ErbB2 is essential in the prevention of dilated cardiomyopathyNature Medicine, 2002
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- Gα i2 but Not Gα i3 Is Required for Muscarinic Inhibition of Contractility and Calcium Currents in Adult CardiomyocytesCirculation Research, 2000
- Adenoviral Gene Transfer of Activated Phosphatidylinositol 3′-Kinase and Akt Inhibits Apoptosis of Hypoxic Cardiomyocytes In VitroCell Metabolism, 1999
- Absence of autophosphorylation site Y882 in the p185neu oncogene product correlates with a reduction of transforming potentialOncogene, 1998
- Involvement of the neuregulins and their receptors in cardiac and neural developmentBioEssays, 1996